Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Avecia, TriLink form oligos pact

March 6, 2006 | A version of this story appeared in Volume 84, Issue 10

Avecia Biotechnology and TriLink BioTechnologies are integrating their oligonucleotide operations to offer customers a seamless transition when scaling up from research to the clinic. TriLink offers small-scale oligos for the discovery and preclinical stages of drug development, while Avecia has capabilities spanning clinical to commercial scale. The companies say that harmonizing their technologies simplifies the regulatory process, minimizes risk, and saves both time and money for oligo customers.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.